Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Anika Therapeutics (ANIK) EBIAT (2016 - 2026)

Anika Therapeutics has reported EBIAT over the past 17 years, most recently at -$5.1 million for Q1 2026.

  • Quarterly EBIAT fell 27.74% to -$5.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$11.3 million through Mar 2026, up 69.0% year-over-year, with the annual reading at -$10.9 million for FY2025, 23.24% down from the prior year.
  • EBIAT was -$5.1 million for Q1 2026 at Anika Therapeutics, down from $900000.0 in the prior quarter.
  • Over five years, EBIAT peaked at $16.2 million in Q4 2023 and troughed at -$29.9 million in Q3 2024.
  • The 5-year median for EBIAT is -$4.0 million (2025), against an average of -$4.2 million.
  • Year-over-year, EBIAT skyrocketed 430.64% in 2023 and then plummeted 4411.36% in 2025.
  • A 5-year view of EBIAT shows it stood at -$4.9 million in 2022, then skyrocketed by 430.64% to $16.2 million in 2023, then crashed by 115.32% to -$2.5 million in 2024, then skyrocketed by 136.2% to $900000.0 in 2025, then crashed by 661.78% to -$5.1 million in 2026.
  • Per Business Quant, the three most recent readings for ANIK's EBIAT are -$5.1 million (Q1 2026), $900000.0 (Q4 2025), and -$3.2 million (Q3 2025).